Generic Medicine Info
Indications and Dosage
Diabetic nephropathy in type 2 diabetes mellitus
Adult: Initially, 150 mg once daily, increased up to 300 mg once daily for the maintenance dose.

Adult: Monotherapy or in combination with other antihypertensive agents: 150 mg once daily, may be increased to 300 mg once daily if needed.
Elderly: >75 years Initially, 75 mg once daily.
Special Patient Group
Patient with intravascular volume or salt depletion: Initially, 75 mg once daily.
Renal Impairment
Patients undergoing haemodialysis: Initially, 75 mg once daily.
May be taken with or without food.
Pregnancy. Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2).
Special Precautions
Patient with volume or salt depletion, unstented unilateral or bilateral renal artery stenosis, significant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy, heart failure, diabetes mellitus, ascites due to cirrhosis or refractory ascites, idiopathic or hereditary angioedema, history of angioedema associated with ACE inhibitor therapy. Patient undergoing surgery. Not recommended in patients with primary aldosteronism. Black patients. Renal impairment. Elderly. Lactation.
Adverse Reactions
Significant: Symptomatic hypotension (particularly in patients with salt or volume depletion), renal function deterioration and/or increased serum creatinine, hyperkalaemia, hypoglycaemia (particularly in diabetic patients). Rarely, angioedema.
Blood and lymphatic system disorders: Anaemia, thrombocytopenia.
Cardiac disorders: Tachycardia, chest pain.
Ear and labyrinth disorders: Tinnitus, vertigo.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, dyspepsia.
General disorders and administration site conditions: Fatigue.
Hepatobiliary disorders: Jaundice, hepatitis.
Immune system disorders: Hypersensitivity reactions (e.g. anaphylaxis, anaphylactic shock).
Investigations: Increased plasma creatine kinase, increased liver enzymes.
Musculoskeletal and connective tissue disorders: Musculoskeletal pain, arthralgia, muscle cramps.
Nervous system disorders: Dizziness, headache, orthostatic dizziness.
Skin and subcutaneous tissue disorders: Urticaria, rash.
Vascular disorders: Orthostatic hypotension, flushing.
Patient Counseling Information
This drug may cause dizziness or weariness, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor blood pressure, electrolytes (e.g. serum K levels), serum creatinine, BUN, and urinalysis. Assess for signs of angioedema.
Symptoms: Hypotension, tachycardia, bradycardia. Management: Symptomatic and supportive treatment. May consider administering activated charcoal, inducing emesis, or performing gastric lavage.
Drug Interactions
May increase the serum concentrations and toxicity of lithium. Enhanced hypotensive effect with other antihypertensive agents. Serum K levels may be increased with K-sparing diuretics, K supplements, K-containing salt substitutes, or other drugs that may elevate serum K levels (e.g. heparin). NSAIDs (including selective COX-2 inhibitors) may reduce the antihypertensive effect of irbesartan, and may increase the risk of worsened renal function (including acute renal failure). May increase the serum concentration of repaglinide.
Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and reduced renal function (including acute renal failure) with aliskiren or ACE inhibitors.
Lab Interference
May result in false-negative aldosterone/renin ratio (ARR).
Mechanism of Action: Irbesartan is an angiotensin II receptor antagonist. It blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively binding to angiotensin II receptor type 1 (AT1) receptors.
Onset: 1-2 hours.
Duration: >24 hours.
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Bioavailability: 60-80%. Time to peak plasma concentration: 1.5-2 hours.
Distribution: Volume of distribution: 53-93 L. Plasma protein binding: Approx 96%.
Metabolism: Metabolised in the liver via glucuronide conjugation and oxidation; oxidation is primarily mediated by CYP2C9 isoenzyme.
Excretion: Mainly via faeces (80%); urine (approx 20%; <2% as unchanged drug). Terminal elimination half-life: Approx 11-15 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3749, Irbesartan. Accessed Oct. 26, 2022.

Store between 15-30°C.
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA04 - irbesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Anon. Irbesartan. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 13/10/2022.

Anon. Irbesartan. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 11/10/2022.

Aprovel 150 mg and 300 mg Film-coated Tablets (Sanofi-Aventis [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 11/10/2022.

Avapro Tablet, Film Coated (Sanofi-Aventis U.S. LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 11/10/2022.

Buckingham R (ed). Irbesartan. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 11/10/2022.

Irbesartan Zentiva 75 mg Tablets (Zentiva Pharma UK Limited). MHRA. Accessed 11/10/2022.

Joint Formulary Committee. Irbesartan. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 11/10/2022.

Disclaimer: This information is independently developed by MIMS based on Irbesartan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Aprovel
  • Bezartan
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in